#ASCO22: Unconcerned with later market entry, Arcellx on the up with new BCMA CAR-T data
Arcellx $ACLX has been trading up more than 25% in the last five days, thanks to an ASCO abstract for its Phase I trial for its CAR-T therapy for multiple myeloma. Now, the biotech is ready to reveal an updated picture.
The expanded results on its BCMA-targeting CAR-T therapy include 31 patients, 16 of which have follow-up data for at least one year. Of the 16 patients with 12-month data, 13 showed a complete response to Arcellx’s therapy — a CR rate of 81%.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,600+ biopharma pros reading Endpoints daily — and it's free.